Eutilex.Co.,Ltd (263050.KQ)
- Previous Close
1,213.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 3,700.00 - Volume
0 - Avg. Volume
111,473 - Market Cap (intraday)
48.385B - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea.
www.eutilex.comRecent News: 263050.KQ
View MorePerformance Overview: 263050.KQ
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 263050.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 263050.KQ
View MoreValuation Measures
Market Cap
44.63B
Enterprise Value
41.22B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.97
Price/Book (mrq)
1.26
Enterprise Value/Revenue
3.66
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.94%
Return on Equity (ttm)
-55.84%
Revenue (ttm)
9.53B
Net Income Avi to Common (ttm)
-29.17B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
19.68B
Total Debt/Equity (mrq)
38.30%
Levered Free Cash Flow (ttm)
-13.27B